176 related articles for article (PubMed ID: 23619284)
61. Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.
Boesch M; Zeimet AG; Rumpold H; Gastl G; Sopper S; Wolf D
Stem Cells Transl Med; 2015 Sep; 4(9):1028-32. PubMed ID: 26136502
[TBL] [Abstract][Full Text] [Related]
62. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C; Jansen G; Peters GJ
Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
[TBL] [Abstract][Full Text] [Related]
63. NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway.
Ito M; Kajino K; Abe M; Fujimura T; Mineki R; Ikegami T; Ishikawa T; Hino O
Oncol Rep; 2013 Apr; 29(4):1492-500. PubMed ID: 23354844
[TBL] [Abstract][Full Text] [Related]
64. Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro.
Gu YY; Liu LP; Qin J; Zhang M; Chen Y; Wang D; Li Z; Tang JZ; Mo SL
Fitoterapia; 2014 Apr; 94():21-8. PubMed ID: 24468191
[TBL] [Abstract][Full Text] [Related]
65. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).
Boumendjel A; Nicolle E; Moraux T; Gerby B; Blanc M; Ronot X; Boutonnat J
J Med Chem; 2005 Nov; 48(23):7275-81. PubMed ID: 16279786
[TBL] [Abstract][Full Text] [Related]
66. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
[TBL] [Abstract][Full Text] [Related]
67. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
68. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
69. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
[TBL] [Abstract][Full Text] [Related]
70. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
Zheng LS; Wang F; Li YH; Zhang X; Chen LM; Liang YJ; Dai CL; Yan YY; Tao LY; Mi YJ; Yang AK; To KK; Fu LW
PLoS One; 2009; 4(4):e5172. PubMed ID: 19390592
[TBL] [Abstract][Full Text] [Related]
71. A high-throughput cell-based assay for inhibitors of ABCG2 activity.
Henrich CJ; Bokesch HR; Dean M; Bates SE; Robey RW; Goncharova EI; Wilson JA; McMahon JB
J Biomol Screen; 2006 Mar; 11(2):176-83. PubMed ID: 16490770
[TBL] [Abstract][Full Text] [Related]
72. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
73. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
74. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.
Hegedüs C; Truta-Feles K; Antalffy G; Brózik A; Kasza I; Német K; Orbán TI; Özvegy-Laczka C; Váradi A; Sarkadi B
Biochem Biophys Res Commun; 2012 Apr; 420(4):869-74. PubMed ID: 22449574
[TBL] [Abstract][Full Text] [Related]
75. New use for an old drug: inhibiting ABCG2 with sorafenib.
Wei Y; Ma Y; Zhao Q; Ren Z; Li Y; Hou T; Peng H
Mol Cancer Ther; 2012 Aug; 11(8):1693-702. PubMed ID: 22593228
[TBL] [Abstract][Full Text] [Related]
76. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.
Kowalski P; Farley KM; Lage H; Schneider E
Anticancer Res; 2004; 24(4):2231-5. PubMed ID: 15330166
[TBL] [Abstract][Full Text] [Related]
77. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
[TBL] [Abstract][Full Text] [Related]
78. Metabolites of ginsenosides as novel BCRP inhibitors.
Jin J; Shahi S; Kang HK; van Veen HW; Fan TP
Biochem Biophys Res Commun; 2006 Jul; 345(4):1308-14. PubMed ID: 16729968
[TBL] [Abstract][Full Text] [Related]
79. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
Ifergan I; Scheffer GL; Assaraf YG
Cancer Res; 2005 Dec; 65(23):10952-8. PubMed ID: 16322243
[TBL] [Abstract][Full Text] [Related]
80. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
